amifampridine has been researched along with Amyotrophic Lateral Sclerosis in 2 studies
Amifampridine: 4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aisen, ML | 2 |
| Sevilla, D | 2 |
| Gibson, G | 1 |
| Kutt, H | 1 |
| Blau, A | 1 |
| Edelstein, L | 2 |
| Hatch, J | 1 |
| Blass, J | 2 |
1 trial available for amifampridine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
A double-blind placebo-controlled study of 3,4-diaminopyridine in amytrophic lateral sclerosis patients on a rehabilitation unit.
Topics: 4-Aminopyridine; Administration, Oral; Aged; Amifampridine; Amyotrophic Lateral Sclerosis; Cross-Ove | 1996 |
1 other study available for amifampridine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
3,4-diaminopyridine as a treatment for amyotrophic lateral sclerosis.
Topics: 4-Aminopyridine; Affect; Aged; Amifampridine; Amyotrophic Lateral Sclerosis; Cognition; Female; Huma | 1995 |